Nasus Pharma Ltd. (NSRX) Aandelenanalyse

Bedrijfsoverzicht

Nasus Pharma Ltd. is a clinical-stage specialty pharmaceutical entity dedicated to the development and commercialization of intranasal medications designed to treat acute emergency medical conditions and public health threats. The company operates within the Healthcare sector, specifically in the Drug Manufacturers - General industry, which implies a focus on creating novel therapeutic agents rather than manufacturing generic pharmaceuticals or medical devices. With a current market capitalization of $25.76M and an employee count of 7, Nasus Pharma maintains a very small organizational structure typical of early-stage biotechnology firms. These valuation and headcount figures indicate that the company is in a pre-revenue or early development phase, where value is derived primarily from intellectual property potential and clinical trial progress rather than established sales streams or significant operational scale.

Financiële gezondheid

The reported revenue (TTM) is listed as N/A, while the net income (TTM) stands at a loss of $-5,805,000, and EBITDA is also recorded as N/A. The substantial gap between the nominal revenue figure and the significant net loss reveals a cost structure dominated by research and development expenses that far exceed current operational income, a common characteristic of clinical-stage biopharma companies. The company's free cash flow is reported at $-3,037,000, which indicates a negative financial flexibility position requiring continuous external capital raises to fund ongoing operations and drug development programs. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, reflecting that the company has not yet generated sufficient revenue to cover its variable and fixed costs to achieve profitability. In terms of leverage, the company holds $4.29M in cash against $118,000 in debt, resulting in a debt-to-equity ratio of 4.26, which suggests a balance sheet heavily reliant on equity financing rather than traditional debt structures. Despite the high debt-to-equity ratio, the current ratio of 2.25 indicates a strong short-term liquidity position where current assets are more than double the current liabilities. Return on Equity is listed as N/A due to the lack of net income, while Return on Assets stands at -107.1%, revealing that the company's asset base is generating value at a significant negative rate relative to its total asset value.

Waarderingsbeoordeling

The trailing P/E ratio and forward P/E are both listed as N/A, which implies that standard earnings-based valuation multiples are not applicable until the company transitions from a loss-making status to generating consistent profits. The price-to-book ratio is 7.17, indicating that the market values the company at more than seven times its net asset value, a significant premium often seen in firms with valuable intangible assets like drug candidates. Price-to-sales and EV/EBITDA metrics are also unavailable (N/A), suggesting that traditional revenue-based or enterprise value multiples cannot be applied until the company achieves positive sales and earnings. The stock has traded with a 52-week high of $9.99 and a 52-week low of $1.98, placing the current valuation somewhere within this wide historical range depending on the specific trading day. The beta value is listed as N/A, meaning that the company's specific volatility relative to the broader market cannot be quantified with the provided data.

Growth & Income

Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, preventing a direct comparison of whether earnings are growing faster or slower than revenue. Since the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, confirming that the entity reinvests all available resources into its clinical pipeline and operational growth rather than distributing income to shareholders. The absence of a dividend payout reflects the company's strategy to retain capital for drug development activities essential for advancing its intranasal products. Overall, Nasus Pharma presents a growth and income profile characterized by high-risk, high-potential-reward characteristics typical of clinical-stage pharmaceutical companies with no current dividend income and undefined historical growth rates.